Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016425 | 0.84 | CA1 (0.59) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL345875 | 0.84 | CA1 (0.59) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL3885571 | 0.83 | KMT2A (0.74) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL13932521 | 0.80 | KMT2A (0.71) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL6653763 | 0.80 | KMT2A (0.71) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL9750441 | 0.79 | CA12 (0.66) | KMT2AMEN1MAPTNPC1ALDH1A1 | |
| SCHEMBL5433051 | 0.79 | MAPT (0.65) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL830366 | 0.79 | KMT2A (0.82) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL5057224 | 0.77 | KMT2A (0.54) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL29644794 | 0.76 | ERN1 (0.63) | KMT2AMEN1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960681-B2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORPORATION (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. | 2005-04-07 | — | — | US | disclosed |
| US-6831190-B1 | Acts effectively in stomach, the antibacterial activity becomes weak as the compounds moves from duodenum to small intestines; do not have activity against esylhiacori, staphylococcus aureus, methacycline resistant bacterium | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| EP-1449828-A2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | Nagase ChemteX Corporation (JP) | 2004-08-25 | — | — | EP | disclosed |
| EP-0989112-B1 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORP (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6284791-B1 | USEFUL AS AN ANTI-MICROBIAL AGAINST HELICOBACTER PYLORI | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2001-09-04 | — | — | US | disclosed |
| EP-0775692-B1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEM IND CO LTD (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0989112-A2 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
| EP-0775692-A1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | GCK, ADCY9, ADCY7 | KMT2A 2789/4885MEN1 4345/4885MAPT 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.